Dentsply Sirona to Host Second Quarter Conference Call on July 31st
CHARLOTTE, N.C., July 09, 2024 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced...
Month: July 2024
VYNE Therapeutics Announces Appointment of Subhashis Banerjee, M.D. as Senior Vice President of Clinical Development
Dr. Banerjee previously served as Vice President & Disease Area Head, Rheumatology and Dermatology at Bristol Myers SquibbBRIDGEWATER, N.J., July...
Curonix Receives the First Full-Body Peripheral Nerve Stimulator (PNS) FDA Clearance, including Craniofacial Pain Indication, for its Freedom® PNS System
POMPANO BEACH, Fla., July 09, 2024 (GLOBE NEWSWIRE) -- Curonix LLC, a medical technology company dedicated to relieving chronic pain...
Smith+Nephew is trailblazing a new path for female surgeons with its Orthopaedics for All initiative; a first-of-its-kind global advisory board
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company announces its Orthopaedics for All initiative – a global advisory board established...
Arcutis Provides Update on sNDA for Roflumilast Cream 0.15% for Atopic Dermatitis
WESTLAKE VILLAGE, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing...
AEON Biopharma Announces Strategic Reprioritization to Pursue a Biosimilar Pathway for ABP-450
– Plan to move ahead with a head-to-head comparison to BOTOX® in a cervical dystonia Phase 3 study via the...
ZyVersa Therapeutics’ CEO, Stephen C. Glover, Is an Invited Speaker at H.C. Wainwright 3rd Annual Kidney Conference to be Held Virtually on July 15, 2024
ZyVersa is advancing a dynamic pipeline of drug candidates with multiple programs built around two proprietary technologies – Phase 2a...
Strong Proof-of-Concept Data from Phase 2 Trial of PDE10A Inhibitor (CPL’36), a Novel Oral Antipsychotic
-Statistically significant benefit demonstrated in primary endpoint of positive subscale of the Positive and Negative Syndrome Scale for Schizophrenia (PANSS)...
Emergent BioSolutions Continues to Drive Improved Financial Position as Part of Multi-Year Transformation Plan
GAITHERSBURG, Md., July 09, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today highlights several recent advancements in improving...
Prelude Therapeutics Announces Clinical Collaboration with Merck to Evaluate PRT3789 in Combination with KEYTRUDA® (pembrolizumab) in Patients with SMARCA4-Mutated Cancers
Combining a first-in-class, highly selective SMARCA2 degrader with an anti-PD-1 therapy may potentially enhance the anti-tumor activity of either agent because...
DAS Health Expands Into Canadian Market with Recent Acquisition
Tampa, July 09, 2024 (GLOBE NEWSWIRE) -- DAS Health Ventures, LLC (DAS Health), a provider of healthcare IT and business...
Seyltx Announces Results of Electronic Health Record Analysis to Determine the Prevalence of Refractory Chronic Cough
- Data will be presented at the London International Cough Symposium on July 18, 2024 - 54,958,289 adult patients in...
REMSleep Holdings Inc. Receives 510(K) Clearance on Product
CLEARWATER, Fla., July 09, 2024 (GLOBE NEWSWIRE) -- REMSleep Holdings, Inc. (OTCQB: RMSL) announces the company has been awarded 510(K)...
Opthea Announces Publication on VEGF-C and D Signaling Pathways as Potential Targets for Treatment of Wet AMD
Research underpins sozinibercept’s potential as novel, first-in-class VEGF-C/D ‘trap’ to prevent blood vessel growth and vascular leakage in the retina Published...
Nxera Pharma Webinar Presentation for Q2 FY2024 Financial Results
Tokyo, Japan and Cambridge, UK, 9 July 2024 - Nxera Pharma Co. Ltd (“Nxera”; TSE 4565) will announce its earnings...
Symbeo partners with Amazon Business to extend the reach of its RapidInvoice AP automation solution
Symbeo launches RapidInvoice on Amazon Business’s Market App Center for B2B ecommerce with a solution that enhances AP functions and...
uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington’s Disease
~ Achieved statistically significant, dose-dependent, and durable evidence of potential therapeutic benefit; Patients receiving high-dose AMT-130 showed 80% slowing of...
ORLADEYO® (berotralstat) Approved in Peru
RESEARCH TRIANGLE PARK, N.C., July 09, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the General Directorate...
Tilray Medical Announces Scientific Study on Medical Cannabis for Patients Over Age 50
Older Patients Represent a Rapidly Growing Subset for Therapeutic Medical Cannabis Use for Pain, Sleep, Quality of Life and Co-MedicationBERLIN,...
Obesity Canada Appoints Lisa Schaffer as New Executive Director
EDMONTON, Alberta, July 09, 2024 (GLOBE NEWSWIRE) -- Obesity Canada is pleased to announce the appointment of Lisa Schaffer as...